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ABSTRACT 
Point-of-care diagnostics devices require user-
friendly automation of multi-step / multi-reagent bioana-
lytical protocols. We demonstrate, for the first time, 
Laser-actuated, Centrifugo-Pneumatic Valves (LCPVs) 
which open on-demand by ablating a remotely connected 
polymeric membrane with an instrument-based laser. Due 
to its small footprint, isolation of radiation-induced 
heating from the biological fluids and independence of 
radial position & contact-angle, the novel LCPV 
technology enables large–scale integration of flexibly 
customizable and operationally robust centrifugal 
microfluidic “Lab-on-a-Disc” (LoaD) systems. As a pilot 
application, we demonstrate the detection of Fatty Acid 
Binding Protein and Myeloperoxidase, both potential 
biomarkers used for cardiovascular disease (CVD) 
determination. 
INTRODUCTION 
Nowadays centrifugal microfluidic technologies have 
solidly established in the area of decentralized bioana-
lytical testing, in particular for sample-to-answer automa-
tion of biomedical point-of-care applications. At the 
fluidic backbone of these LoaD systems, liquids 
experience the rotationally controlled centrifugal field in a 
network of microstructures and channels representing 
Laboratory Unit Operations (LUOs), such as metering & 
mixing, connected by interspersed valves [1, 2]. Striking 
benefits of LoaD systems are their inherent capability for 
centrifugal pumping, agitation and particle sedimentation 
based on a simple spindle motor running without error 
prone pneumatic interfaces. Various bioanalytical 
protocols for detecting/ small molecules, proteins, 
antibodies, nucleic acids, cells, bacteria and other bio-
particles have been successfully implemented [3]. 
A range of normally-closed flow control schemes 
have been generated for centrifugal microfluidic platforms 
[2-6]. Such valves are often based on capillary stops and 
siphoning principles. Also sacrificial barrier materials 
such as wax are used; however, these valves tend to be 
difficult to manufacture at the required accuracy and 
reliability while keeping cost low [7]. Other flow barriers 
[8, 9]  directly block liquid flow until opened by high 
intensity electromagnetic irradiation, e.g. a laser. This 
high-energy interaction may lead to chemical modifica-
tion or contamination of the adjacent liquids. 
The burst frequencies of so-called centrifugo-
pneumatic valves that are initially sealed by dissolvable 
films (DF) [10-12] feature a large spread in the definition 
of release frequencies, hence limiting the number of inde-
pendently controlled operations that can be integrated in 
the same disc. Good progress has been made over recent 
years by pneumatically mediated cascading of such DF 
valves to allow comprehensive automation of more com-
plex multi-step, multi-reagent bioanalytical protocols 
[11]. However, the large footprint of these valves is still 
an issue when moving towards higher-level integration of 
fluidic networks on the LoaD. 
We present here a new type of laser-actuated centri-
fugo-pneumatic valves (LCPVs). In their initial state, 
liquid is prevented from entering the valve by compres-
sion of entrapped gas. Exposure of the control film (CF) 
by an instrument-based laser vents the pneumatic cham-
ber, thus allowing the liquid to wet and subsequently exit 
through the DF. 
There are several advantages of these LCPVs: Com-
pared to direct membrane blocking of the flow, the ther-
mal impact is localized at a distal CF, and thus well insu-
lated from the liquid to avoid its potential damage and 
contamination. Furthermore, their “digital” nature renders 
the flow control mechanism largely independent of its 
radial position, manufacturing tolerances and capillary 
effects. The small footprint facilitates use of the LCPVs a 
good candidate for high-density process integration of 
fluidic networks. Additionally, focusing of the ‘contact-
free’ laser actuation enables selective opening of CFs that 
are vertically distributed across stacked disc layers 
through focusing on their respective optical plane. 
SYSTEM DESIGN 
We demonstrate here the design, operation and 
application of the new LCPV technology based on laser 
perforation of a polymeric barrier films. In their default, 
normally-closed state, these thin CFs seal a pneumatic 
chamber created between the incoming fluid reservoir / 
microchannel and the exit channel sealed with a DF. The 
3D architecture (Fig. 1) is constituted by structured 
PMMA discs bonded by interspersed layers of pressure 
sensitive adhesive (Fig. 2) [11]. As they are either trans-
parent or exhibit a local ‘cut-out’, the CFs in different 
layers can be addressed by vertical translation of the laser 
(Fig. 2B). This configuration offers wide flexibility of the 
placement of the LCPV as long as a pneumatic chamber is 
still formed between the CF, the DF and the incoming 
liquid under the impact of the centrifugal field. 
Figure 3 illustrates the functional principle of the 
LCPV. At the outset, liquid in the reservoir is held back 
from wetting the DF on the exit channel under the impact 
of the centrifugo-pneumatic compression of the trapped 
gas pocket according to Boyle’s law. Once the laser 
pierces the thin CF in about ~1 s, the pneumatic chamber 
is vented and the liquid can proceed to wet and thus open 
the DF tab that so far blocked the exit channel below.  
 
Figure 1: Basic LCPV configuration. While the CF and 
the DF are intact, the incoming water from the reservoir 
(in blue) entraps a gas pocket between the LCPV, DF and 
the water (labelled Pneumatic chamber + microchannel). 
When the CF is laser-ablated on-demand, the pneumatic 
chamber is vented to the atmosphere via the lower vents 
in the base layer of a multi-layered disc. Driven by the 
centrifugal force, the water then proceeds to wet and 
dissolve the DF to let the liquid proceed to the exit 
channel. 
 
Thus, LCPVs provide a simple, on-demand, small-
footprint technique that also allows release of liquids 
widely independent of their radial position and surface 
wettability. This allows for higher-level system inte-
gration and parallelization of multi-sample and multi-
analyte assay protocols. We demonstrate this by fully 
automating the entire sample handling protocol for 
detecting a potential multi-marker panel of CVD 
diagnostics. 
 
BIOMARKER ASSAY AUTOMATION  
CVD comprises a wide range of diseases and ab-
normal conditions affecting the heart or coronary vessels. 
The development of a rapid, sufficiently sensitive and 
specific tool for diagnostics and early-stage prognostics is 
highly desirable [13, 14]. So far, commercially available 
cardiac biomarker POC devices have focused mainly on 
the detection of myoglobin and cardiac troponins [15]. 
However, instead of relying on a sole marker, it is now 
suggested that biomarker panels featuring a combination 
of select markers may significantly improve diagnosis of 
CVD [16]. 
We now employ an LCPV-controlled LoaD 
system to automate the liquid handling protocol at the 
backbone of an ELISA including all the steps from initialt 
plasma extraction to incubation, buffer washes and the 
final enzymatic reaction for signal generation (Fig. 4). 
This technology will pave the way towards 
implementation of a sample-to-answer device for the 
point-of-care detection of at least three cardiac biomarkers 
and corresponding controls (we demonstrate two here). 
The compact valve design even allows reserving space for 
further parameters. 
 
Figure 2: A) The laser actuates through multiple layers of 
PMMA and PSA (as long as they are transparent or allow 
modification for light to pass through) allowing wide 
range X-Y actuation.  B) The focal point of the laser can 
be moved in order to actuate several membranes along 
the vertical (Z) direction, thus allowing to reach any 
deeply recessed valve in the system. (1-8 are the layers of 
the LoaD with red layers designating pressure sensitive 
adhesive and the transparent thick layers being PMMA 
plastic) 
For the current study, two CVD biomarkers, 
Heart-Type Fatty Acid Binding Protein (hFABP) and My-
eloperoxidase (MPO) are detected using a competitive 
ELISA format. The concentration of hFABP is known to 
rise during cardiac necrosis and is thus a sensitive indica-
tor of ischemia in acute myocardial infarction [17]. Detec-
tion of MPO within a hospital setting was shown to be a 
potential risk predictor for primary cardiac incidents [18]. 
 
EXPERIMENTAL PROTOCOL 
Benchtop Competitive ELISA: 
Half the area of 96-well plates (Fisher, Ireland) were 
coated with 30 μL per well of 2.5 μg mL-1 hFABP or 
2 μg mL-1 MPO (AMS Biotechnologies, UK) at 4°C over-
night. Plates were blocked with 60 μL per well of 5% 
(w/v) Milk Marvel in Phosphate Buffered Saline Tween-
A 
B 
20 (PBST) at 37°C for one hour. The plate was washed 
with Phosphate Buffered Saline (PBS) (60 μL / well). To 
carry out the competitive ELISA, a range of concen-
trations of FABP (0-500 ng mL-1) or MPO (0-2000 ng 
mL-1) were prepared and mixed with a fixed concentration 
of antiFABP scFv (0.26 μg mL-1) and anti-MPO 
(0.03 μg mL-1) scFv. This mixture (30 μL / well) was 
incubated at room temperature for 10 min. A negative 
control, consisting of 30 μL / well of ‘FABP-free’ human 
sera and MPO free human sera was incorporated. The 
plate was washed with PBS (60 μL / well). Then HRP-
labeled anti-HA antibody (1:1,000, 30 μL/well) was 
added (the scFv have a HA tag) and incubated at room 
temperature for 10 min. The plate was washed with PBS 
(60 μL / well). TMB (0.4 g L-1, 30 μL / well), the HRP 
substrate, was added and incubated at room temperature 
for 2 min. The reaction was stopped by addition of 30 μL 
of 1M HCl per well. The absorbance of the wells was read 
at 450 nm using a Safire 2 plate reader. 
 
 
Figure 3: Release mechanism for the opto-pneumatic 
valves. A. The reservoir is loaded with aqueous solution. 
A pressurized pneumatic chamber is created (in green) 
between the CF and the DF which prevents the liquid 
from priming the exit channel and wetting of the DF. B. 
Laser irradiation (415 nm, ~1 sec) releases the pressure 
in the pneumatic chamber via a vent on the base layer. C. 
The microchannel is immediately primed and wets the 
DF. D. The dissolution of the DF releases the liquid into 
the lower channel en route to the next chamber and the 
reservoir is emptied by increasing the spin frequency.  
 
LoaD Competitive ELISA: 
The disc is a hybrid assembly of three layers of 
poly-methyl methacrylate (PMMA), a base layer of poly-
styrene (for immobilization) along with four layers of 
pressure sensitive adhesive (Adhesives Research, Lime-
rick, Ireland). The manufacturing method and assembly 
have been described elsewhere [11, 19]. 
 
Figure 4: 
Multi-marker 
LoaD with 
seven sections, 
liquid 
chambers and 
LCPV valves. 
Chamber: A-
Blood, B-
Plasma 
metering, C- 
Incubation 
and detection, 
D-Waste, E- 
First Buffer 
Wash, F- 
Second Buffer 
Wash, G- Stop 
Acid, H- 
Secondary 
Antibody, I- 
TMB 
colorimetric 
substrate. 
 
 
 
 
 
 
 
 
To prepare the discs, the incubation chambers 
were coated with 30 μL per chamber of 5 μg mL-1 FABP) 
dissolved in PBS what pH at 4°C for overnight. The incu-
bation chambers were blocked with 60 μL per chamber 
5% (w/v) PBSTM at 37°C for one hour. The upper covers 
of the incubation chamber in the vents and microchannel 
layers are also blocked with PBSTM before finally 
sealing the disc before testing. The incubation chambers 
were then washed once using PBS (60 μL per well) and 
dried using pressurized air. The disc was sealed and taken 
for testing. 
 
RESULTS 
Figures 5 and 6 show the results of the manual benchtop 
and the LoaD results for the competitive ELISA based 
detection of spiked FABP and MPO concentrations from 
‘FABP and MPO-free’ human serum, respectively. The 
LoaD is capable of detecting the CVD biomarker panel 
from serum within the same range as the benchtop 
protocol. The sensitivity may be further improved by 
addressing adverse factors such as denaturation of the 
proteins on the disc surface and enhanced blocking. 
 
 
Figure 5: LoaD (blue) versus benchtop (green) 
competitive ELISA of anti-FABP antibodies in human 
serum. The A/A0 values were plotted as a function of the 
target antigen concentration after 10 minutes (The absor-
bance with no FABP competition was referred to as A0). 
For the LoaD negative control, the absorbance with 
’FABP-free’ serum alone was used (n = 2). 
 
Figure 6: LoaD (blue) versus benchtop (green) 
competitive ELISA of anti-MPO antibodies in human 
serum. The A/A0 values were plotted as a function of the 
target antigen concentration after 10 minutes (The 
absorbance with no MPO competition was referred to as 
A0). For the LoaD negative control, the absorbance with 
purely MPO free serum was used (n = 2). 
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